MindWalk (HYFT) Competitors

$1.20 -0.07 (-5.16%)

As of 03:16 PM Eastern

HYFT vs. KROS, MDWD, CNTX, HUMA, and UNCY

Should you buy MindWalk stock or one of its competitors? MarketBeat compares MindWalk with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with MindWalk include Keros Therapeutics (KROS), MediWound (MDWD), Context Therapeutics (CNTX), Humacyte (HUMA), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical products" industry.

How does MindWalk compare to Keros Therapeutics?

MindWalk (NASDAQ:HYFT) and Keros Therapeutics (NASDAQ:KROS) are both small-cap pharmaceutical products companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Keros Therapeutics has a net margin of 35.65% compared to MindWalk's net margin of -66.79%. Keros Therapeutics' return on equity of 14.25% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Keros Therapeutics	35.65%	14.25%	13.27%

MindWalk has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Keros Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 71.6% of Keros Therapeutics shares are owned by institutional investors. 6.8% of MindWalk shares are owned by insiders. Comparatively, 20.6% of Keros Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Keros Therapeutics had 1 more articles in the media than MindWalk. MarketBeat recorded 3 mentions for Keros Therapeutics and 2 mentions for MindWalk. MindWalk's average media sentiment score of 0.93 beat Keros Therapeutics' score of -0.53 indicating that MindWalk is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Keros Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Keros Therapeutics has higher revenue and earnings than MindWalk. MindWalk is trading at a lower price-to-earnings ratio than Keros Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$28.08M	1.96	-$21.69M	-$0.20	N/A
Keros Therapeutics	$244.06M	0.85	$87.01M	$1.82	5.74

MindWalk currently has a consensus price target of $5.00, suggesting a potential upside of 318.41%. Keros Therapeutics has a consensus price target of $20.40, suggesting a potential upside of 95.29%. Given MindWalk's stronger consensus rating and higher possible upside, research analysts clearly believe MindWalk is more favorable than Keros Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Keros Therapeutics	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Keros Therapeutics beats MindWalk on 12 of the 17 factors compared between the two stocks.

How does MindWalk compare to MediWound?

MediWound (NASDAQ:MDWD) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk.

MindWalk has higher revenue and earnings than MediWound. MediWound is trading at a lower price-to-earnings ratio than MindWalk, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MediWound	$16.96M	12.44	-$23.88M	-$2.10	N/A
MindWalk	$28.08M	1.96	-$21.69M	-$0.20	N/A

MediWound has a beta of 0.21, indicating that its stock price is 79% less volatile than the broader market. Comparatively, MindWalk has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

46.8% of MediWound shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 9.2% of MediWound shares are held by company insiders. Comparatively, 6.8% of MindWalk shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

MindWalk has a net margin of -66.79% compared to MediWound's net margin of -140.80%. MediWound's return on equity of -65.79% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MediWound	-140.80%	-65.79%	-30.16%
MindWalk	-66.79%	-69.37%	-39.74%

MediWound presently has a consensus target price of $35.00, indicating a potential upside of 113.22%. MindWalk has a consensus target price of $5.00, indicating a potential upside of 318.41%. Given MindWalk's stronger consensus rating and higher possible upside, analysts clearly believe MindWalk is more favorable than MediWound.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MediWound	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, MediWound and MediWound both had 2 articles in the media. MediWound's average media sentiment score of 0.94 beat MindWalk's score of 0.93 indicating that MediWound is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MediWound	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MindWalk	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

MindWalk beats MediWound on 9 of the 15 factors compared between the two stocks.

How does MindWalk compare to Context Therapeutics?

MindWalk (NASDAQ:HYFT) and Context Therapeutics (NASDAQ:CNTX) are both small-cap pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, profitability and analyst recommendations.

Context Therapeutics has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Context Therapeutics' return on equity of -59.95% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Context Therapeutics	N/A	-59.95%	-54.78%

In the previous week, Context Therapeutics had 13 more articles in the media than MindWalk. MarketBeat recorded 15 mentions for Context Therapeutics and 2 mentions for MindWalk. Context Therapeutics' average media sentiment score of 1.01 beat MindWalk's score of 0.93 indicating that Context Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Context Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MindWalk presently has a consensus target price of $5.00, suggesting a potential upside of 318.41%. Context Therapeutics has a consensus target price of $6.60, suggesting a potential upside of 204.85%. Given MindWalk's higher probable upside, research analysts clearly believe MindWalk is more favorable than Context Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Context Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

MindWalk has higher revenue and earnings than Context Therapeutics. MindWalk is trading at a lower price-to-earnings ratio than Context Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$28.08M	1.96	-$21.69M	-$0.20	N/A
Context Therapeutics	N/A	N/A	-$36.12M	-$0.42	N/A

6.7% of MindWalk shares are held by institutional investors. Comparatively, 14.0% of Context Therapeutics shares are held by institutional investors. 6.8% of MindWalk shares are held by insiders. Comparatively, 4.8% of Context Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

MindWalk has a beta of 0.65, indicating that its share price is 35% less volatile than the broader market. Comparatively, Context Therapeutics has a beta of 1.57, indicating that its share price is 57% more volatile than the broader market.

Summary

Context Therapeutics beats MindWalk on 9 of the 15 factors compared between the two stocks.

How does MindWalk compare to Humacyte?

MindWalk (NASDAQ:HYFT) and Humacyte (NASDAQ:HUMA) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends, media sentiment and risk.

6.7% of MindWalk shares are owned by institutional investors. Comparatively, 44.7% of Humacyte shares are owned by institutional investors. 6.8% of MindWalk shares are owned by company insiders. Comparatively, 3.1% of Humacyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MindWalk presently has a consensus target price of $5.00, suggesting a potential upside of 318.41%. Humacyte has a consensus target price of $7.57, suggesting a potential upside of 708.91%. Given Humacyte's stronger consensus rating and higher possible upside, analysts clearly believe Humacyte is more favorable than MindWalk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60
Humacyte	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.75

MindWalk has a beta of 0.65, meaning that its share price is 35% less volatile than the broader market. Comparatively, Humacyte has a beta of 2.31, meaning that its share price is 131% more volatile than the broader market.

MindWalk has higher revenue and earnings than Humacyte. MindWalk is trading at a lower price-to-earnings ratio than Humacyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MindWalk	$28.08M	1.96	-$21.69M	-$0.20	N/A
Humacyte	$2.04M	101.87	-$40.83M	-$0.20	N/A

In the previous week, Humacyte had 10 more articles in the media than MindWalk. MarketBeat recorded 12 mentions for Humacyte and 2 mentions for MindWalk. MindWalk's average media sentiment score of 0.93 beat Humacyte's score of 0.06 indicating that MindWalk is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MindWalk	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Humacyte	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

MindWalk has a net margin of -66.79% compared to Humacyte's net margin of -4,836.06%. MindWalk's return on equity of -69.37% beat Humacyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MindWalk	-66.79%	-69.37%	-39.74%
Humacyte	-4,836.06%	-12,727.47%	-88.48%

Summary

MindWalk and Humacyte tied by winning 8 of the 16 factors compared between the two stocks.

How does MindWalk compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings.

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of MindWalk shares are owned by institutional investors. 10.7% of Unicycive Therapeutics shares are owned by company insiders. Comparatively, 6.8% of MindWalk shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Unicycive Therapeutics has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. MindWalk's return on equity of -69.37% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-134.69%	-84.51%
MindWalk	-66.79%	-69.37%	-39.74%

MindWalk has higher revenue and earnings than Unicycive Therapeutics. MindWalk is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	323.74	-$26.56M	-$2.17	N/A
MindWalk	$28.08M	1.96	-$21.69M	-$0.20	N/A

Unicycive Therapeutics has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market.

Unicycive Therapeutics presently has a consensus target price of $24.00, indicating a potential upside of 191.09%. MindWalk has a consensus target price of $5.00, indicating a potential upside of 318.41%. Given MindWalk's higher possible upside, analysts clearly believe MindWalk is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

In the previous week, Unicycive Therapeutics had 18 more articles in the media than MindWalk. MarketBeat recorded 20 mentions for Unicycive Therapeutics and 2 mentions for MindWalk. MindWalk's average media sentiment score of 0.93 beat Unicycive Therapeutics' score of 0.06 indicating that MindWalk is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Unicycive Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MindWalk	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Unicycive Therapeutics beats MindWalk on 9 of the 17 factors compared between the two stocks.

Get MindWalk News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HYFT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HYFT vs. The Competition

Export

Metric	MindWalk	Pharmaceutical Preparations Industry	Manufacturing Sector	NASDAQ Exchange
Market Cap	$55.16M	$923.92M	$4.19B	$12.32B
Dividend Yield	N/A	4.84%	6.42%	5.35%
P/E Ratio	-5.98	1.45	22.71	25.37
Price / Sales	1.96	117.25	156.17	73.28
Price / Cash	N/A	20.07	53.46	56.33
Price / Book	3.23	8.34	39.09	6.93
Net Income	-$21.69M	-$3.77M	$113.55M	$333.88M
7 Day Performance	-5.91%	9.39%	2.97%	0.33%
1 Month Performance	-6.64%	60.76%	4.88%	2.11%
1 Year Performance	N/A	114.56%	16.68%	33.31%

MindWalk Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HYFT MindWalk	3.0084 of 5 stars	$1.20 -5.2%	$5.00 +318.4%	N/A	$55.16M	$28.08M	N/A	80
KROS Keros Therapeutics	3.0927 of 5 stars	$11.64 -1.2%	$21.33 +83.3%	-19.1%	$233.10M	$244.06M	6.40	100	News Coverage Earnings Report
MDWD MediWound	2.2922 of 5 stars	$17.27 -0.6%	$35.00 +102.7%	-13.5%	$223.24M	$16.96M	N/A	80	News Coverage Upcoming Earnings High Trading Volume
CNTX Context Therapeutics	3.4446 of 5 stars	$2.33 -3.3%	$6.60 +183.3%	+194.9%	$221.43M	N/A	N/A	7
HUMA Humacyte	2.4938 of 5 stars	$1.08 +9.8%	$7.71 +614.3%	-46.5%	$218.31M	$2.04M	N/A	150	Earnings Report Analyst Forecast Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HYFT) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

MindWalk (HYFT) Competitors

HYFT vs. KROS, MDWD, CNTX, HUMA, and UNCY

How does MindWalk compare to Keros Therapeutics?

Summary

How does MindWalk compare to MediWound?

Summary

How does MindWalk compare to Context Therapeutics?

Summary

How does MindWalk compare to Humacyte?

Summary

How does MindWalk compare to Unicycive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

MindWalk (HYFT) Competitors

HYFT vs. KROS, MDWD, CNTX, HUMA, and UNCY

How does MindWalk compare to Keros Therapeutics?

Is HYFT or KROS more profitable?

Which has more risk and volatility, HYFT or KROS?

Do insiders & institutionals believe in HYFT or KROS?

Does the media favor HYFT or KROS?

Which has stronger valuation and earnings, HYFT or KROS?

Do analysts rate HYFT or KROS?

Summary

How does MindWalk compare to MediWound?

Which has better valuation and earnings, MDWD or HYFT?

Which has more risk and volatility, MDWD or HYFT?

Do institutionals and insiders believe in MDWD or HYFT?

Is MDWD or HYFT more profitable?

Do analysts recommend MDWD or HYFT?

Does the media favor MDWD or HYFT?

Summary

How does MindWalk compare to Context Therapeutics?

Is HYFT or CNTX more profitable?

Does the media refer more to HYFT or CNTX?

Do analysts recommend HYFT or CNTX?

Which has better earnings & valuation, HYFT or CNTX?

Do insiders & institutionals hold more shares of HYFT or CNTX?

Which has more risk and volatility, HYFT or CNTX?

Summary

How does MindWalk compare to Humacyte?

Do institutionals & insiders hold more shares of HYFT or HUMA?

Do analysts recommend HYFT or HUMA?

Which has more risk & volatility, HYFT or HUMA?

Which has preferable earnings and valuation, HYFT or HUMA?

Does the media favor HYFT or HUMA?

Is HYFT or HUMA more profitable?

Summary

How does MindWalk compare to Unicycive Therapeutics?

Do insiders & institutionals hold more shares of UNCY or HYFT?

Is UNCY or HYFT more profitable?

Which has higher valuation and earnings, UNCY or HYFT?

Which has more risk and volatility, UNCY or HYFT?

Do analysts rate UNCY or HYFT?

Does the media prefer UNCY or HYFT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HYFT vs. The Competition

MindWalk Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools